Highly specific, next-generation NAMPT inhibitor, that reduces the viability of most B-ALL cell lines with high potency demonstrating IC50 values in the low nanomolar range, and improves survival in an orthotopic xenotransplant model of high-risk acute lymphoblastic leukemia. Additionally, STF 118804 induces leukemia cell apoptosis without antecedent cell cycle arrest, and targets leukemia stem cells.

KEYWORDS: STF 118804 | supplier | NAMPT inhibitor | STF118804 | CAS [894187-61-2] | Nicotinamide D-ribonucleotide | NAD | NAD+ | apoptosis | leukemia | cell cycle | arrest | stem cells